No abstract

I disease, 28,729 (88%) received AC and only 3,876 (12%) received NAC. Complete response (ypT0/isN0) (pCR) was achieved in 7,302 of 30,527 patients (24%). Crude death rate was significantly different in AC, NAC-pCR and NAC-non-pCR: 12.7%, 5.5% and 26.9% respectively (p < 0.01). Overall, NAC non-pCR was significantly associated with worse OS. For patients with cStage IIA disease, NAC did not confer OS benefits.CONCLUSION: NAC-non-pCR is associated with worse unadjusted outcomes as expected. However, NAC did not appear to improve outcomes in patients with cStage IIA eTNBC. Future work to elucidate the clinical benefits of emerging novel NAC strategies in eTNBC will be of interest.